MARKET

NCNA

NCNA

NuCana
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.49
+0.22
+3.51%
Closed 16:00 06/01 EDT
OPEN
6.20
PREV CLOSE
6.27
HIGH
6.63
LOW
6.06
VOLUME
77.84K
TURNOVER
--
52 WEEK HIGH
13.50
52 WEEK LOW
3.810
MARKET CAP
210.79M
P/E (TTM)
-8.4340
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NCNA stock price target is 16.60 with a high estimate of 21.45 and a low estimate of 13.28.

EPS

NCNA News

More
Will NuCana Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor of NuCana
Zacks · 19h ago
NuCana (NCNA) Investor Presentation - Slideshow
Seeking Alpha - Article · 3d ago
Top Ranked Momentum Stocks to Buy for May 28th
Zacks · 4d ago
NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference
GlobeNewswire · 6d ago
3 Strong Buy Healthcare Stocks That Could Double in the Next Year
TipRanks · 05/24 12:00
64 Biggest Movers From Yesterday
Gainers
Benzinga · 05/22 09:26
51 Stocks Moving In Thursday's Mid-Day Session
Gainers Seneca Biopharma, Inc. (NASDAQ: SNCA) jumped 99% to $1.6350.
Benzinga · 05/21 17:18
ACB, NBR, NNVC and SPN among midday movers
Seeking Alpha - Article · 05/21 16:42

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About NCNA

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for cancer patients using its ProTide technology. Its pipeline includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. Acelarin is designed to generate and maintain higher concentrations of the anti-cancer metabolite inside the tumor. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). NUC-3373 is being developed for patients with advanced solid tumors. It is developing NUC-3373 as a therapy for colorectal cancer and other solid tumors. NUC-7738 is a ProTide of 3’-deoxyadenosine and is able to enter cells independently of nucleoside transporters. It is developing NUC-7738 for patients with either solid or hematological malignancies.
More

Webull offers kinds of NuCana PLC (ADR) stock information, including NASDAQ:NCNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NCNA stock news, and many more online research tools to help you make informed decisions.